A detailed history of Quest Partners LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Quest Partners LLC holds 584 shares of RARE stock, worth $19,318. This represents 0.0% of its overall portfolio holdings.

Number of Shares
584
Previous 7,642 92.36%
Holding current value
$19,318
Previous $278 Million 93.68%
% of portfolio
0.0%
Previous 0.03%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 03, 2025

SELL
$26.31 - $41.44 $185,695 - $292,483
-7,058 Reduced 92.36%
584 $17.6 Million
Q2 2025

Jul 31, 2025

SELL
$31.06 - $39.3 $101,783 - $128,786
-3,277 Reduced 30.01%
7,642 $278 Million
Q1 2025

May 14, 2025

BUY
$36.21 - $45.78 $99,649 - $125,986
2,752 Added 33.7%
10,919 $395 Million
Q4 2024

Feb 07, 2025

BUY
$42.07 - $57.72 $253,345 - $347,589
6,022 Added 280.75%
8,167 $344 Million
Q3 2024

Nov 07, 2024

BUY
$40.21 - $59.36 $86,250 - $127,327
2,145 New
2,145 $119 Million
Q1 2024

May 09, 2024

BUY
$43.02 - $53.69 $495,676 - $618,616
11,522 New
11,522 $538 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.32B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.